Influence of magnesium valproate and quetiapine separately combined with lithium carbonate on BRMS score, PANSS score and adverse effects of patients with manic episode of bipolar disorder in puberty
0
Citation
0
Reference
20
Related Paper
Abstract:
Objective
To investigate the influence of magnesium valproate and quetiapine separately combined with lithium carbonate on BRMS scores, PANSS scores and adverse effects of patients with manic episode of bipolar disorder in puberty.
Methods
100 patients with manic episode of bipolar disorder in puberty were chosen and randomly divided into two groups according to the digital table.Group A (50 children) was given magnesium valproate, and group B (50 children) was given quetiapine on the basis of lithium carbonate.The clinical efficacy, the BRMS score, PANSS score and WCST score before and after treatment and the incidence of adverse effects of the two groups were compared.
Results
There was no significant difference in clinical efficacy between the two groups(94.00% vs.90.00%), (χ2=1.31, P>0.05). After treatment for 2 weeks, the BRMS score, PANSS score and WCST score of group B were significantly better than those of group A and before treatment(t=2.45, 3.16; 2.71, 3.26, 2.79, 3.36, all P 0.05).
Conclusion
Two kinds of bigeminy drug therapy in the treatment of patients with manic episode of bipolar disorder in puberty possess the clinical effects and safety, and quetiapine combined with lithium can help to shorten the onset time and higher the compliance degree.
Key words:
Bipolar disorder; Magnesium valproate; Quetiapine; Lithium carbonateKeywords:
Lithium carbonate
Objective
To explore the effects of quetiapine combined with sertraline in the treatment of schizophrenia patients with depressive symptoms.
Methods
86 patients of convalescence of schizophrenia with depression symptoms were randomly divided into quetiapine combined with sertraline group(observation group) and quetiapine group(control group). The treatment course was 8 weeks.Before and after treatment, the positive and negative symptoms scale (PANSS) and Hamilton depression scale(HAMD) were assessed in the two groups.The curative effect of quetiapine combined with sertraline on the schizophrenia patients with depression symptoms was explored.
Results
Pre-treatment, there were no differences in the two groups on PANSS score(t=-0.432, P>0.05), HAMD score (t=0.424, P>0.05). Post-treatment, there were significant differences between the two groups in PANSS score (t=18.780, P<0.05; t=12.256, P<0.05) and HAMD score (t=6.542, P<0.05; t=4.107, P<0.05). There were significant differences between the two groups in HAMD score (t=6.612, P<0.05).
Conclusion
Quetiapine can significantly improve the effects of positive and negative symptoms and depressive symptoms of schizophrenia patients with depression symptoms.Quetiapine combined with sertraline can improve the depressive symptoms of schizophrenia better compared with quetiapine.
Key words:
Quetiapine; Sertraline; Depressive Symptoms; Schizophrenia
Sertraline
Depression
Hamilton depression scale
Cite
Citations (0)
Introduction Although there is no cure, schizophrenia is highly treatable disease. Successful first episode schizophrenia (FES) treatment is crucial to minimize personal, vocational and social deterioration. Quetiapine is atypical, second generation antipsychotic, serotonin-dopamine antagonist. Quetiapine is potent blocker of D2, 5HT2A and 5HT1A receptors. Objective To estimate efficacy of quetiapine in treatment of first episode schizophrenia. Methods This study included 70 patients with FES diagnosed by ICD-10 criteria, who are divided into haloperidol (H) 35 patients and quetiapine (Q) group 35 patients. Patients were observed for 6 months in hospital and extra hospital conditions, according to protocol which included Positive and Negative Symptom Schedule Scale (PANSS) and the number of withdrawals attributed to adverse event (AE). Control group was treated with haloperidol 5–20 mg/24 h and experimental group was treated with quetiapine 400–800 mg/24 h. Results Average pretrial PANSS score was 110.1 in quetiapine and 108.5 in haloperidol group. Average PANSS score after 180 days was 50.6 in Q and 60.4 in H group. There is no statistical difference in pretrial scores between groups for PANSS score ( P = 0.647). There is significant statistical difference in PANSS score reduction after 180 days in both groups ( P < 0.001). There is significant statistical difference in PANSS score reduction between Q and H group after 180 days ( P < 0.001). Overall, 8.6% AEs occurred in Q, and 25.8% in H group. Conclusion Quetiapine has shown better efficacy in treatment of FES comparing to haloperidol, with statistically significant lower adverse effects rate. Disclosure of interest The authors have not supplied their declaration of competing interest.
Quetiapine Fumarate
Tolerability
Cite
Citations (0)
Objective The study was to explore the effectiveness and safety of chronic combination treatment of magnesium valproate with quetiapine on recurent mania.Method All 66 affective disorder patients with mania-onset were randomly assigned to receive magnesium valproate(n=33),and magnesium valproate with quetiapine(n=33),In acute phase treatment of 6 weeks after 5 years.At baseline,the symptom was evaluated with the Bech-Rafaelsen Manin Rating Scale(BRMS).The drug dosage,times of relapse,effectsand safety was compared among the three groups.Results After the acute therapy,the reductions in BRMS score were(42±27)% in magnesium valproate group,(57±24)% in combination group,respectively,with significant differences between the two groups(P0.05).At followed-up 5 years,mania relapse times was significantly less in combination group than that in magnesium valproate group(mean times of 1.9±1.6,3.3±2.0,P0.01);depression relapse times was no differences in both groups(mean times of 1.8±2.0,1.9±1.8,P0.05).The mean dosage of single drug in combination groups was significantly lower than that in magnesium valproate(P0.01).There were no significantly statistic differences on side-effects two groups.Conclusion It is suggested that the efficacy of combination therapy of magnesium valproate with quetiapine on mania be better than monotherapy with magnesium valproate with the same safety.
Combination therapy
Cite
Citations (0)
Objective To explore efficacy and safety of quetiapine combining valproate in the treatment of patients with acute aminc episode of bipolar I disorder.Methods Sixty patients meeting the criteria of DSM-Ⅳ for Bipolar I disorder acute manic episodes were randomly divided into stduy group(n=30) treated with quetiapine combining valproate and control group(n=30) treated with quetiapine monotherapy for 6 weeks.Clinical efficacy was evaluated with Bech-Rafaelsen Mania Rating Scale(BRMS) and Clinical Global Impression(CGI),side effects was evaluated with Treatment Emergent Symptom Scale(TESS).Results Scores of BRMS at the 6th weekend in the two groups both decreased significantly compared with those at the baseline(P0.05).The decreasing rate of BRMS at the 1st weekend in study group was significantly higher than that in control group,and the difference lasted for the whole course of treatment(P0.05).At the end of the treatment,the recovery rate in study group was significantly higher than that in control group(P0.01).No serious adverse events happened in the two groups.There was no significant difference in dropout rate due to inefficacy and side effects.Conclusion The efficacy of quetiapine combining with valproate is better than that of valproate monotherapy in treatment of acute aminc episode of bipolar I disorder.The combining therapy takes effect more quickly and its safety is good.
Clinical Global Impression
Bipolar I disorder
Clinical efficacy
Cite
Citations (0)
Objective To observe the effectiveness and safety of quetiapine combined with sodium valproate in the treatment of bipolar disorder manic. Methods From March 2012 to March 2014,80 patients with bipolar disorder manic treated in our hospital were selected and randomly divided into the research group(n=40) and control group(n=40).The control group was given quetiapined,while the research group was given quetiapine combined with sodium valproate.The course of treatment lasted 8 weeks.The therapeutic effect was evaluated by Bech-Rafaelsen mania scale(BRMS).The total effective rate,the incidence rate of adverse reaction in the two groups were compared. Results After 4,8 weeks treatment,BRMS score of the research group was greatly lower than that in the control group with a statistical difference(P 0.05). After 8 weeks treatment,there was no statistical difference of the total effective rate in the two groups(P 0.05). There was a statistical difference of the incidence rate of adverse reaction in the two groups(P 0.05).Conclusion Quetiapine combined with sodium valproate in the treatment of bipolar disorder manic obtains a definite therapeutic effect.It is safe and reliable,and is worthy of clinical expansion and application.
Cite
Citations (0)
AIM:To explore efficacy and safety of ziprasidone combining lithium carbonate or valproate in the treatment of patients with manic and mixed episode of bipolar disorders. METHODS:The 68 patients meeting criteria of manic episode or mixed episode of bipolar disorder in CCMD-3 were randomly divided into experiment group(combination of ziprasidone and lithium carbonate or valproate) and control group(single using of lithium carbonate or valproate) and observed for 6 weeks.The Yong Manic Rating Scale(YMRS) and treatment emergent symptom scale(TESS)were individually used for the assessment of efficacy and safety. RESULTS:The score of YMRS was decreased significantly in the both groups after treatment(F=9.05,P0.01;F=6.10,P0.01).And the score of YMRS at 1st weekend in experiment group was significantly higher than that in control group,and this difference sustained for 6 weeks.The cure rate in experiment group was higher than that in control group after treating for 6 weeks.The scores of YMRS in experiment group were 21.4±8.4,14.6±5.5,8.9±3.3,6.5±3.4,respectively at 1 weekend,2 weekend and 3 weekend;and the scores of YMRS in control group were 23.9±7.2,20.9±8.1,17.8±7.8,12.8±8.9,respectively.There was significant difference between the experiment group and control group(P0.01).The changes of decreasing score of symptoms were in experiment group 6.1±3.5,12.9±4.8,20.1±5.3,21.4±5.5;and the changes of decreasing score of symptoms in control group were 2.1±3.0,6.8±4.5,11.5±5.6,14.4±5.3,respectively.There was significant difference between the experiment group and control group(P0.01).The effective rate and cure rate in experiment group was significantly higher than that in control group(68.5% vs 48.5%,χ2=4.47,P0.05;54.3%vs 18.2%,χ2=9.52,P0.01).Both groups have not serious side effects.There were no difference in dropout rate due to less efficacy and side effects. CONCLUSION:The effects of ziprasidone combination with lithium carbonate or valproate in the treatment of manic episode and mixed episode of bipolar disorder is better than that of single lithium carbonate or valproate.
Ziprasidone
Bipolar I disorder
Mood stabilizer
Lithium carbonate
Cite
Citations (0)
Objective:To explore the efficacy and safety of oxcarbazepine and lithium in treatment of bipolar disorder with mania episode. Method:70 patients with bipolar disorder with mania episode randomized into single used oxcarbazepine group(35 cases) and lithium group(35 cases) for 8 weeks.Bech-Rafaelsen manic scale(BRMS) ,clinical global impressions severity scale(CGI-SI) and treatment emergent symptoms scale(TESS) were used to evaluate efficacy and side effects. Results:After treatment,BRMS and CGI-S score decreased significantly compared with before treatment(P0.05 or P0.01) ,there were no significant difference between two groups in score of BRMS and CGI-S(P0.05) .Two groups adverse events were mild. Conclusion:Oxcarbazepine and lithium are both effective and safe,in the treatment of bipolar disorder with manic episode.
Oxcarbazepine
Cite
Citations (0)
Objective To explore the efficacy and safety of quetiapine vs.Lithium carbonate in the treatment of bipolar disorder manic episode(BDME).Methods Sixty-eight BDME patients were randomly assigned to two groups of 34 ones each,research group took orally quetiapine and control group did lithium carbonate for 6 weeks.Clinical efficacies were assessed with the Beck-Rafaelsen Mania Scale(BRMS) and Treatment Emergent Symptom Scale(TESS) before treatment and at the end of the 2nd,4th and 6nd week.Results Score of study group decreased significantly than the control group in the second week,the difference between groups was significant.Scores of two groups were significantly decreased in the 6th weeks,difference between groups was not significant,adverse reactions of two groups were no significant differences.Conclusion Ziprasidone combined with lithium is rapid onset,curative effects,less adverse reaction and higher security in treatment of manic episodes of bipolar disorder.
Ziprasidone
Lithium carbonate
Bipolar I disorder
Hypomania
Cite
Citations (0)
Objective To explore the clinic effect and security between quetiapine and risperidone in the treatment of female schizophrenia.Methods From May 2012 to May 2015,300 female schizophrenics were randomly assigned into two groups of 150 patients each,research group were given quetiapine and the control group given fispefidone treatment for eight weeks.The Positive and Negative Symptoms Scale(PANSS)were used for the evaluation before and after 8 weeks treatment and the Treatment Emergent Symptom Scale(TESS)for drug interactions with observations.Results The PANSS scores of the two groups after 8 weeks treatment were both lower significantly than that of before treating(P0.05).Comparison between the two groups,the research group patients' PANSS scores were slightly less than the control group(P0.05).The adverse reaction rate of the research group were significantly lower than that of the control group in extrapyramidal reaction and menopause lactation(P0.05).Conclusion Quetiapine and risperidone both have good therapeutics effect for female schizophrenia with no significant difference,but quetiapine has lower adverse reaction rate and higher safety,and quetiapine is more suitable for female people to use.
Extrapyramidal symptoms
Cite
Citations (0)
Objective
To compare the treatment effects and adverse reactions of sodium valproate and quinolapine combined with lithium carbonate for patients with episodes bipolar disorder.
Methods
Sixty-eight patients with episodes bipolar disorder were included in this study, and they were divided into two groups according to the random method, with 34 cases in each group. The group A was treated with quetiapine and lithium carbonate, while the group B was treated with sodium valproate and lithium carbonate. Then, the differences of clinical effects and safety of the two groups after the treatment for 4 weeks were evaluated.
Results
There was no significant difference in BRMS or PANSS scores, the total treatment efficiency, the incidence of adverse reactions or the frequency of manic episodes, the number of hospitalization or the hospitalization time after the treatment for 4 weeks between the group A and group B (P>0.05). But after 1 week of treatment, the score of BRMS and PANSS in group A was significantly lower than that in group B (P<0.05).
Conclusions
On the basis of lithium carbonate, the clinical effect and safety of sodium valproate combined with quetiapine in the treatment of episodes bipolar disorder are good, and the quetiapine are faster and more beneficial to the early recovery of the patients.
Key words:
Episodes bipolar disorder; Sodium valproate; Quinolapine; Lithiumcarbonate; Clinical effect
Lithium carbonate
Cite
Citations (0)